Oncologix Tech is a clinical-stage biotech company specializing in advanced oncology diagnostics and digital pathology solutions. With a focus on integrating artificial intelligence and machine learning into cancer detection, the company develops next-generation platforms aimed at improving early diagnosis and treatment monitoring. Oncologix Tech’s proprietary technologies enable pathologists and clinicians to analyze tissue samples with greater speed and accuracy, supporting more informed therapeutic decisions across a range of solid tumor types.
The company’s core product portfolio includes a cloud-based image analysis system that leverages deep learning algorithms to identify and quantify tumor biomarkers in histological slides. In addition, Oncologix Tech offers a suite of companion diagnostic assays designed to guide targeted therapies, as well as software tools for remote slide review and telepathology consultations. These offerings are complemented by contract research services, including digital pathology consultation, clinical trial endpoint support, and custom AI model development for pharmaceutical and academic partners.
Founded in 2012 and headquartered in Philadelphia, Oncologix Tech serves a global customer base spanning North America, Europe and Asia-Pacific. The company has established strategic collaborations with leading medical centers and research institutions to validate its platforms in multicenter clinical studies. Over the past decade, Oncologix Tech has expanded its footprint through a combination of in-house R&D, academic spin-off projects and licensing agreements that have accelerated the commercialization of its diagnostic solutions.
The management team is led by CEO Dr. Jane Morrison, a veteran in oncology diagnostics with more than 25 years of experience in translational research and medical device development. Supporting her is a leadership group that includes a chief scientific officer with a background in computational biology and a chief technology officer who oversaw commercialization of several AI-driven imaging platforms. Together, they guide Oncologix Tech’s efforts to drive innovation in precision oncology and to collaborate with healthcare providers worldwide to improve patient outcomes.
AI Generated. May Contain Errors.
Free OCLG Stock Alerts